紫杉醇药物涂层球囊成形术治疗症状性椎动脉开口处狭窄的疗效

目的 探讨紫杉醇药物涂层球囊（P-DCB）成形术治疗症状性椎动脉开口狭窄的安全性和有效性。方法 回顾性分析2017 年12月至2019年6月经P-DCB成形术治疗的43例症状性椎动脉开口处狭窄的临床资料。结果 所有病人均完成介入治疗，成功率为100%。术后即刻狭窄率（12.03±2.15）%]较术前（86.32±10.26）%]明显降低（P<0.05）。围手术期发生动脉夹层1例，无其他并发症。随访12~16个月，平均13.5个月；症状改善43例，无变化例，症状改善率为95.3%（41/43）；全部病人接受DSA或CTA随访，随访狭窄率（16.1±3.12）%]与术后即刻无统计学差异（P>0.05）；5例发生再狭窄，再狭窄率为11.6%。结论 P-DCB成形术治疗椎动脉开口狭窄具有较好的临床疗效。

Paclitaxel drug-coated balloon angioplasty for patients with symptomatic vertebral artery origin stenosis

Objective To evaluate the efficacy and safety of paclitacxel drug-coated balloon(P-DCB)angioplasty for the patients with symptomatic vertebral artery origin stenosis(VARS).Methods The clinical data of 43 consecutive patients with symptomatic VARS who underwent P-DCB angioplasty from December 2017 to June 2019 were analyzed retrospectively.Results All the procedures were completed successfully,and the success rate was 100%.The immediate postoperative stenosis rate(12.03±2.15)%]was significantly lower than that(86.32±10.26)%]before the operation(P<0.05).Arterial dissection occurred in 1 patient during the perioperative period.The follow-up ranged from 12 months to 16 months,with an average of 13.5 months.The symptomatic improvement rate was 95.3%(41/43).There was no statistical difference between the follow-up stenosis rate(16.1±3.12)%]and the immediate postoperative stenosis rate(P>0.05).Restenosis occurred in 5 patients and the restenosis rate was 11.6%(5/43).Conclusion P-DCB angioplasty is a safe and good method for treatment of the patients with symptomatic VARS.